OTCMKTS:NWBO Northwest Biotherapeutics (NWBO) Stock Price, News & Analysis $0.17 0.00 (0.00%) As of 07/24/2026 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock About Northwest Biotherapeutics Stock (OTCMKTS:NWBO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get NWBO alerts:Sign Up Key Stats Today's Range$0.17▼$0.1750-Day Range$0.15▼$0.2552-Week Range$0.14▼$0.37Volume1.47 million shsAverage Volume3.81 million shsMarket Capitalization$289.84 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Northwest Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of personalized dendritic cell immunotherapies for the treatment of cancer. The company’s proprietary platform harnesses patient-derived dendritic cells to present tumor-specific antigens and stimulate a targeted immune response. By tailoring each vaccine to the individual patient’s tumor profile, the approach aims to improve outcomes and reduce off-target toxicity associated with conventional therapies. The company’s lead candidate, DCVax®-L, is designed for patients with newly diagnosed or recurrent glioblastoma multiforme (GBM) and has advanced through a global Phase III clinical trial. In addition, Northwest Biotherapeutics is evaluating DCVax®-Direct, a novel formulation intended for direct injection into solid tumors, in Phase I/II studies. The company maintains an active pipeline exploring applications of its dendritic cell platform in other oncology indications. Headquartered in Bethesda, Maryland, Northwest Biotherapeutics collaborates with research institutions and clinical centers across North America and Europe. These partnerships support ongoing trials, manufacturing scale-up, and regulatory interactions. The company’s leadership team comprises industry veterans with expertise in immunology, clinical development, and regulatory affairs, all working to advance personalized immunotherapy as a new standard of care in oncology.AI Generated. May Contain Errors. Read More Northwest Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks5th Percentile Overall ScoreNWBO MarketRank™: Northwest Biotherapeutics scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Northwest Biotherapeutics. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Northwest Biotherapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Northwest Biotherapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Northwest Biotherapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.25% of the float of Northwest Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverNorthwest Biotherapeutics has a short interest ratio ("days to cover") of 9.24.Change versus previous monthShort interest in Northwest Biotherapeutics has recently increased by 2.14%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNorthwest Biotherapeutics does not currently pay a dividend.Dividend GrowthNorthwest Biotherapeutics does not have a long track record of dividend growth. News and Social Media3.0 / 5News SentimentN/A News SentimentNorthwest Biotherapeutics has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Northwest Biotherapeutics this week, compared to 0 articles on an average week.MarketBeat Follows2 people have added Northwest Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Northwest Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders2.40% of the stock of Northwest Biotherapeutics is held by insiders.Percentage Held by Institutions0.04% of the stock of Northwest Biotherapeutics is held by institutions.Read more about Northwest Biotherapeutics' insider trading history. Receive NWBO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Northwest Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NWBO Stock News HeadlinesNorthwest Biotherapeutics (OTCMKTS:NWBO) Shares Pass Below 200-Day Moving Average - Should You Sell?July 25 at 3:21 AM | americanbankingnews.comNORTHWEST BIOTHRPUTCS INC by Northwest Biotherapeutics, Inc. Insider Trading ActivityJuly 18, 2026 | benzinga.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account. | Profits Run (Ad)Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Passes Below 200-Day Moving Average - Here's What HappenedJuly 17, 2026 | americanbankingnews.comNorthwest Biotherapeutics, Inc.: Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax-L For Glioblastoma Using Individual Patient Level Data ...July 8, 2026 | finanznachrichten.deNorthwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent AnalysesJuly 8, 2026 | prnewswire.comNorthwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual MeetingJuly 2, 2026 | prnewswire.comNorthwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine PlatformApril 30, 2026 | prnewswire.comSee More Headlines NWBO Stock Analysis - Frequently Asked Questions How have NWBO shares performed this year? Northwest Biotherapeutics' stock was trading at $0.23 at the beginning of the year. Since then, NWBO shares have decreased by 25.3% and is now trading at $0.1717. How were Northwest Biotherapeutics' earnings last quarter? Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) released its quarterly earnings data on Friday, November, 14th. The biotechnology company reported ($18.22) earnings per share for the quarter. The biotechnology company earned $0.20 million during the quarter. How do I buy shares of Northwest Biotherapeutics? Shares of NWBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Northwest Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Northwest Biotherapeutics investors own include Clearside Biomedical (CLSD), Ocular Therapeutix (OCUL), NVIDIA (NVDA), Intel (INTC), Advanced Micro Devices (AMD) and Meta Platforms (META). Company Calendar Last Earnings11/14/2025Today7/27/2026Next Earnings (Estimated)8/13/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:NWBO Previous SymbolNASDAQ:NWBO CIK1072379 Webwww.nwbio.com Phone(240) 497-9024Fax240-627-4121Employees20Year Founded1998Profitability EPS (Trailing Twelve Months)($18.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$60.16 million Net Margins-2,931.73% Pretax Margin-2,967.60% Return on EquityN/A Return on Assets-79.26% Debt Debt-to-Equity RatioN/A Current Ratio0.07 Quick Ratio0.07 Sales & Book Value Annual Sales$1.38 million Price / Sales210.03 Cash FlowN/A Price / Cash FlowN/A Book Value($0.04) per share Price / Book-4.29Miscellaneous Outstanding Shares1,688,070,000Free Float1,647,560,000Market Cap$289.84 million OptionableNot Optionable Beta-0.63 Social Links 10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (OTCMKTS:NWBO) was last updated on 7/27/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredWhere to Put $100 Before Trump's New Tech Law Rolls OutThe Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...Brownstone Research | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Northwest Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Northwest Biotherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
